Company News

AESI CEO Forfeits Shares at $13.60 as Six-Month Insider Selling Trend Reaches 582,124 Shares

AESI CEO Forfeits Shares at $13.60 as Six-Month Insider Selling Trend Reaches 582,124 Shares

CEO John Gregory Turner forfeited 16,130 shares at $13.60 for tax withholding, part of a six-month pattern showing 582,124 net…

Ulta Beauty CEO Kecia Steelman Surrenders 1,491 Shares at $535.72 in Tax Withholding Transaction

Ulta Beauty CEO Kecia Steelman surrendered 1,491 shares at $535.72 in a tax withholding transaction, part of a three-executive cluster…

BLDR CEO Peter Jackson and 7 Executives Surrender $2.77M in Shares for Tax Withholdings

CEO Peter Jackson and seven executives surrendered 31,470 shares worth $2.77M in tax withholdings, while insiders remain net buyers over…

ANDE Insider Patrick E. Bowe Sells 15,000 Shares at $70.41

Patrick E. Bowe sold 15,000 shares at $70.41, part of a six-month pattern showing 61,598 shares sold with zero insider…

The Andersons, Inc. 2025 Financial Performance

VP & Treasurer Brian K. Walz sold 8,975 shares at $70.74, part of a six-month pattern of net insider selling…

Benchmark Electronics (BHE) Maintains $0.17 Quarterly Dividend, 1.25% Yield With March 31 Ex-Date

Benchmark Electronics maintains $0.17 quarterly dividend with March 31 ex-date, yielding 1.25% at declaration price.

NBIS Stock Plunges 11.9% to $114.43 Despite Three Analyst Upgrades

NBIS shares fell 11.9% to $114.43 despite three analyst upgrades, with no clear fundamental catalyst for the $3.9 billion market…

Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected

Trevi Therapeutics narrows Q4 loss to $0.06 per share, beating estimates by 37% as the pre-revenue biotech maintains unanimous analyst…

Solaris Energy Infrastructure: 2025 Performance Report

Solaris Energy Infrastructure beats adjusted EPS estimates by 41.5% but misses on revenue as capital spending drives negative free cash…

Kestra Medical (KMTS) Revenue Surges 62.7% YoY to $24.6M; Loss Narrows

Kestra Medical posted a slightly wider-than-expected Q3 loss of $0.61/share, but revenue surged 63% year-over-year to top estimates.